SECsense Logo

Lipella Pharmaceuticals Inc. 8-K Report: Key Financial Insights as of December 27, 2024

$LIPO
Form 8-K
Filed on: 2024-12-27
Source
Lipella Pharmaceuticals Inc. 8-K Report: Key Financial Insights as of December 27, 2024

Based on the provided section of the financial report, here are the key pieces of information and insights:

  1. Entity Identification:
  • Company Name: Lipella Pharmaceuticals Inc.
  • CIK (Central Index Key): 0001347242
  • SEC File Number: 005-93847
  • EIN (Employer Identification Number): 20-2388040
  1. Reporting Period:
  • Report Date: December 27, 2024
  • Context Period: The reporting is as of a single date (December 27, 2024), making it a snapshot financial report.
  1. Location and Contact Information:
  • Address: 7800 Susquehanna St., Suite 505, Pittsburgh, PA 15208
  • Phone Number: (412) 894-1853
  1. Security Information:
  • Type of Security: Common Stock
  • Par Value: $0.0001 per share
  • Ticker Symbol: LIPO
  • Stock Exchange: NASDAQ
  1. Units of Measure:
  • The report uses USD (United States Dollar) for monetary values and 'shares' for the number of shares.
  1. Key Attributes:
  • The report represents a financial statement that is likely focused on a specific event or update, as indicated by the 8-K filing, which typically covers significant events that shareholders should know about.

Insights:

  • Market Presence: Lipella Pharmaceuticals is listed on NASDAQ, indicating it is a publicly traded company, which can impact its access to capital and investor scrutiny.
  • Business Nature: Being a pharmaceuticals company, market dynamics such as drug approvals, research and development, and regulatory changes will significantly impact its performance.
  • Financial Reporting: The use of the 8-K form suggests that Lipella Pharmaceuticals is communicating important information that could affect stock prices and investor decisions, highlighting the company's transparency and regulatory compliance.

This summary encapsulates the critical components of the financial report, which are essential for stakeholders to assess the company's current operational status and market positioning.